Recursion Pharmaceuticals Inc (RXRX) — Cash Flow Reinvestment Rate

Latest as of March 2022: 1.96x

Recursion Pharmaceuticals Inc (RXRX) has a Cash Flow Reinvestment Rate of 1.96x as of March 2022, reinvesting $151.99 Million (capex $4.34 Million plus investments $147.65 Million) from operating cash flow of $77.39 Million. Explore RXRX capex to operating cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.

Reinvestment Rate

1.96x
(Capex + Investments) / Operating CF

Total Reinvested

$151.99 Million
Capex + Investments

Operating Cash Flow

$77.39 Million
USD

Capital Expenditures

$4.34 Million
USD

Annual Cash Flow Reinvestment Rate for Recursion Pharmaceuticals Inc (None–None)

Year-by-year capital reinvestment analysis for Recursion Pharmaceuticals Inc. For live market cap and broader valuation context, see RXRX stock market capitalisation.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow